Barclays analyst Luke Sergott lowered the firm’s price target on Catalent to $58 from $62 and keeps an Overweight rating on the shares. The analyst says 2023 will likely be a “tale of 2 cities” for traditional tools verses bioprocessing names. The year likely favors conservative management teams with a history of beating estimates, the firm tells investors in a research note.
Published first on TheFly
Read More on CTLT: